Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Current pharmaceutical design ; h5-index 57.0

Deep learning, an emerging field of artificial intelligence based on neural network in machine learning, has been applied in various fields and is highly valued. Herein we mainly review several mainstream architectures in deep learning, including deep neural networks, convolutional neural networks and recurrent neural networks in the field of drug discovery. The applications of several architectures in molecular de novo design, property prediction, biomedical imaging and synthetic planning have also been explored. We also discuss the future direction of the deep learning approaches and the main challenges we need to address.

Wang Feng, Diao XiaoMin, Chang Shan, Xu Lei


artificial intelligence, biomedical imaging, de novo design, deep learning, drug discovery, neural networks, property prediction, synthetic planning.\n \n